Background This retrospective study investigated overall survival (OS) and factors
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …

Purpose To review the treatment of metastatic renal cell carcinoma (RCC), including the use
of new targeted therapies. Methods A search of MEDLINE (1966 to August 2008) and …

For many years, therapy for metastatic renal cell carcinoma (mRCC) was limited to a single
line of cytokine therapy with either interferon or interleukin-2. Relatively recently, the novel …

BACKGROUND: The increased finding of kidney 'incidentalomas' and more frequent surgery
in patients with renal cell cancer (RCC) metastases may have improved survival from the …

Metastatic renal cell carcinoma has been considered to be resistant to chemotherapy, with
responses observed in only limited numbers of patients. For this reason, therapeutic options …

The treatment of renal cell carcinoma has dramatically changed in the past 6 years with the
approval of seven new drugs since 2006. although treatment algorithms have been reported …

Opinion statement In general, debulking neprhectomy is still considered for metastatic RCC
patients with primary tumor in place, assuming good performance status. Initial systemic …

BACKGROUND: The survival impact of metastasectomy for metastatic renal cell carcinoma
(mRCC) is still an active research field, particularly in the multimodal/targeted therapy era …

The use of targeted agents to treat metastatic renal cell carcinoma (mRCC) has significantly
extended progression-free and overall survival but raises issues relating to the long-term …

Simple Summary The management of metastatic renal cell carcinoma (mRCC) represents a
clinical challenge. Progression or toxicity may occur during first-line treatments and many …